Aurlumyn is a drug owned by Btg International Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 18, 2044. Details of Aurlumyn's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12409183 | NA |
Jul, 2044
(18 years from now) | Active |
| US12409184 | NA |
Aug, 2041
(15 years from now) | Active |
FDA has granted several exclusivities to Aurlumyn. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Aurlumyn, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Aurlumyn.
Exclusivity Information
Aurlumyn holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Aurlumyn's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-465) | Feb 13, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Aurlumyn is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Aurlumyn's family patents as well as insights into
ongoing legal events
on those patents.
Aurlumyn's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aurlumyn's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 18, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aurlumyn Generics:
There are no approved generic versions for Aurlumyn as of now.
About Aurlumyn
Aurlumyn is a drug owned by Btg International Inc. Aurlumyn uses Iloprost as an active ingredient. Aurlumyn was launched by Btg Intl in 2024.
Approval Date:
Aurlumyn was approved by FDA for market use on 13 February, 2024.
Active Ingredient:
Aurlumyn uses Iloprost as the active ingredient. Check out other Drugs and Companies using Iloprost ingredient
Dosage:
Aurlumyn is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MCG/ML (100MCG/ML) | SOLUTION | Prescription | INTRAVENOUS |